Author: Ken Dropiewski

STRONG-HF study results demonstrate clear benefits for acute heart failure patients

STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implemented Rapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life. The Roche Elecsys® NT-proBNP biomarker is an integral part of the treatment […]

Applied Therapeutics Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In […]

American Society of Echocardiography Releases New EchoGuide™ App

The mobile and web app provides quick access to common and challenging echocardiography measurements and values DURHAM, NC, Nov. 09, 2022 (GLOBE NEWSWIRE) — The American Society of Echocardiography (ASE) announced today that it is launching a new interactive mobile and web application for healthcare professionals providing cardiac care. EchoGuide™ is a calculator and […]

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — Royalty […]

Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus

– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers – – Virtual Program Begins at 10am ET Today, Wednesday, November 9th – ANN ARBOR, Mich., Nov. […]

SVS Foundation Adds DEI Pillar

Contact: Beth Bales Senior Communications Manager, SVS (312) 334-2316 ROSEMONT, ILL. (Nov. 9, 2022) ­– The Society for Vascular Surgery (SVS) Foundation has been guided by the three long-term pillars of research and innovation, community vascular care and patient education, and disease prevention. Recently, the Foundation added a fourth pillar […]

AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented a new analysis […]

Implicity to Participate in Health Tech Challengers Super Finals at HLTH 2022

Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health. CAMBRIDGE, Mass., Nov. 8, 2022 /PRNewswire/ — Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health […]